ArticleJACS Au2026
Formal Chemoenzymatic Skeletal Editing of Fusicoccane Core to Access 6‑Aza-Fusicoccanes.
Article in JACS Au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fusicoccane (FC)-type diterpenoids constitute a family of cyclic diterpenoids featuring a 5/8/5-fused tricyclic carbon skeleton. These natural products have attracted considerable attention owing to their unique biological functions, including plant hormone-like properties and antiproliferative activities against cancer cells. Herein, we report the stereoselective synthesis of 6-aza-FC-type analogs via a chemoenzymatic skeletal editing approach using CotB2, a diterpene synthase responsible for constructing the FC skeleton. Based on the biosynthetic reaction mechanism, we designed an unnatural substrate bearing an amide moiety at the C6-C7 position of geranylgeranyl pyrophosphate. CotB2 promoted the cyclization of this substrate to afford an optically active 5/11-fused lactam in a stereoselective manner. Subsequent intramolecular cyclization of the resulting lactam through an epoxide intermediate furnished 6-aza-FC derivatives, in which the C6 carbon of FC skeleton is replaced with a nitrogen atom. Notably, one of the 6-aza-FC analogs exhibited selective cytotoxicity toward cancer cells, while displaying reduced activity toward HUVEC cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.